Merck & Co. Inc.

10/19/2025 | Press release | Distributed by Public on 10/19/2025 07:01

Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Merck & Co. Inc. published this content on October 19, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 19, 2025 at 13:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]